Trial record 1 of 1 for:
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Combination Study for High Risk Multiple Myeloma Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03104270 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 7, 2017
Last Update Posted : August 14, 2020
|
Sponsor:
Oncotherapeutics
Information provided by (Responsible Party):
Oncotherapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2020 |
| Estimated Study Completion Date : | October 2020 |